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The FGFR4-388arg Variant 
Promotes Lung Cancer Progression 
by N-Cadherin Induction
Álvaro Quintanal-Villalonga1, Laura Ojeda-Márquez1, Ángela Marrugal1, Patricia Yagüe1, 
Santiago Ponce-Aix1,4, Ana Salinas2, Amancio Carnero2,4, Irene Ferrer1,4, Sonia Molina-Pinelo2,4 & 
Luis Paz-Ares1,3,4
The FGFR4-388Arg variant has been related to poor prognosis in several types of cancer, including lung 
cancer. The mechanism underlying this association has not been addressed in detail in patients with 
this pathology. Here, we report that this FGFR4 variant induces MAPK and STAT3 activation and causes 
pro-oncogenic effects in NSCLC in vitro and in vivo. This variant induces the expression of EMT-related 
genes, such as N-cadherin, vimentin, Snail1 and Twist1. Indeed, the induction of N-cadherin protein 
expression by this variant is essential for its pro-tumorigenic role. The presence of the FGFR4-388Arg 
variant correlates with higher N-cadherin expression levels in clinical NSCLC samples and with poorer 
outcome in patients with FGFR expression. These results support the prognostic role of this FGFR 
variant in lung cancer and show that these effects may be mediated by the induction of N-cadherin 
expression and an EMT phenotype.
The incidence and mortality of lung cancer are increasing worldwide1. Lung cancer is a heterogeneous disease 
that can be classified into two major histologically distinct groups: small cell lung cancer (SCLC) and non-small 
cell lung cancer (NSCLC), which accounts for 85% of primary lung carcinomas2. Among NSCLC cases, adeno-
carcinoma (ADC) and squamous cell cancer (SCC) are the most frequent histological subtypes. Currently, lung 
cancer accounts for the majority of cancer-related deaths; the dismal prognosis of patients with lung cancer is due 
to the common presentation with advanced stage disease at initial diagnosis and the relative inefficacy of available 
systemic treatment. Indeed, the expected 5-year survival rate is 18%3. Therefore, the identification of relevant 
diagnostic biomarkers and novel and druggable targets for this disease represents an unmet clinical need.
In recent years, many molecular alterations with a significant role in tumor pathogenesis and the outcome of 
cancer patients have been identified. Many such alterations have involved tyrosine kinase receptors4, which have 
proven therapeutic potential in a variety of cancer types. One such tyrosine kinase receptor is FGFR4, which 
has been associated with prognosis in several types of cancer, including lung cancer5–7. Several molecular alter-
ations of FGFR4 leading to different gene variants have been identified8. One of these variants, FGFR4–388Arg 
(rs351855 at the genotype level), harbors an amino acid substitution of an arginine for a glycine at codon 388. This 
FGFR4 variant correlates with disease progression and poorer prognosis in colon, prostate, head and neck, breast, 
and soft tissue tumors, among many others9–15. Nonetheless, the effects of this FGFR4 variant in NSCLC patient 
prognosis seem to be controversial. In a study involving Asian NSCLC patients, the FGFR4-388Arg variant corre-
lated with poorer outcome in patients with lymph node involvement16. However, contradictory results have been 
reported in other studies. In a work involving advanced NSCLC Asian patients, the FGFR4-388Arg variant cor-
related with better outcome17, and in another study involving Caucasian NSCLC patients, no association between 
this FGFR4 variant and outcome was found18. In some retrospective studies of lung cancer cohorts analyzing 
each histological subtype independently, the FGFR4-388Arg variant was linked to lymph node involvement and 
poorer overall survival (OS) in ADC patients13,16,18,19. For SCC patients, however, association of this variant with 
prognosis has been described only in lymph node-involved patients18–20.
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The FGFR4-388Arg variant has been reported to promote the activation of pathways related to cancer, such as 
the STAT3 signaling pathway in murine breast and lung cancer models21. In addition, overexpression of FGFR4-
388Arg was reported to induce MAPK activation and promote proliferation and invasion in in vitro models 
of prostate cancer22. Furthermore, this FGFR4 variant has been related to epithelial-to-mesenchymal transition 
(EMT) in prostate cancer cell lines23. In this work, we aimed to study the effect of the FGFR4-388Arg variant on 
lung cancer oncogenic behavior, its relationship with EMT in this setting, and its impact on patient prognosis.
Results
The FGFR4-388Arg variant shows increased tumorigenic potential in vitro and in vivo. To 
ascertain the impact of the FGFR4-388Arg variant on the tumorigenic behavior of lung cell lines, we overex-
pressed the FGFR4-388Gly and FGFR4-388Arg alleles in three lung cell lines that lacked endogenous FGFR4 
expression and performed surrogate assays of tumorigenic activity. We selected cell lines with different genetic 
backgrounds (Supplementary Table S1): one immortalized cell line (NL20), two SCC cell lines (H226 and Calu-1) 
and two ADC cell lines (H2009 and HCC827). In the NL20, H226, Calu-1 and HCC827 cell lines, ectopic FGFR4-
388Gly expression increased cell growth, and clonogenicity and soft agar colony formation compared to the 
empty vector control, and FGFR4-388Arg elicited a greater increase in these tumorigenic activities (Fig. 1A,B and 
Supplementary Figure S1). We then determined the activation status of downstream FGFR cancer-related signa-
ling pathways (specifically, the STAT3, AKT and MAPK pathways) in these cell lines; Generally, FGFR4-388Arg 
overexpression increased pSTAT3 and p-42/p44 levels compared to their respective empty vector control and 
FGFR4-388Gly overexpressing cell lines. However, AKT signaling was similarly activated in the cell lines over-
expressing either FGFR4 variant (Fig. 1C). When we analyzed the effects of overexpressing each variant allele in 
the lung ADC H2009 cell line, we found that cell growth was slightly reduced by FGFR4-388Gly overexpression 
but was increased by FGFR4-388Arg overexpression compared to the empty vector control (Fig. 1A). Equivalent 
results were obtained in the clonogenicity and soft agar assays: in H2009 cells, the empty vector produced more 
colonies than FGFR4-388Gly but fewer colonies than FGFR4-388Arg (Fig. 1B and Supplementary Figures S1). 
When the activation of FGFR-related signaling pathways was assessed by western blot, the activation of STAT3, 
AKT and ERK was decreased in FGFR4-388Gly-overexpressing H2009 cells but increased in FGFR4-388Arg-
overexpressing H2009 cells compared to those expressing the empty vector control (Fig. 1C). These results show 
that although FGFR4-388Gly seems to exert differential effects on tumorigenesis in the cell lines tested, FGFR4-
388Arg has a consistent pro-oncogenic role in different lung cancer cell lines. Furthermore, these tumorigenic 
effects correlate with greater activation of STAT3 and MAPK signaling.
To test the in vivo tumorigenic effects of the FGFR4-388Arg variant, we xenografted into nude mice the ade-
nocarcinoma cell line H2009 and the squamous cell carcinoma cell line H226 overexpressing either FGFR4 vari-
ant. According to the in vitro results, we reported that FGFR4-388Gly overexpression in these xenografts caused 
decreased tumor growth in the H2009 cell line, and increased tumor growth in the H226 cell line, as compared 
to their respective control cell lines. However, in both cases, FGFR4-388Arg overexpression caused higher tumor 
growth, as compared to the rest of conditions (Fig. 2).
FGFR4-388Arg variant overexpression induces an epithelial-to-mesenchymal transition phe-
notype in lung cancer cell lines. It has been reported in other tumor models that silencing FGFR4-388Arg 
induces a mesenchymal-to-epithelial transition, suggesting a role for FGFR4-388Arg in EMT22,24. To explore 
whether FGFR4-388Arg overexpression induces EMT in lung cell lines, we measured the mRNA and protein 
levels of several EMT markers (N-cadherin, Twist1, vimentin, and Snail1) in the FGFR4-388Gly- and FGFR4-
388Arg-overexpressing cell lines. FGFR4-388Gly overexpression in the five cell lines did not alter the mRNA 
levels of any of the studied EMT markers compared to their respective empty vector-expressing cell line. However, 
FGFR4-388Arg overexpression increased the mRNA and protein levels of N-cadherin, vimentin, Snail1 and 
Twist1 (Fig. 3A,B). In addition, we tested the migration ability of these cell lines as a functional assay for EMT 
induction. While FGFR4-388Gly overexpression did not increase migration, as compared to the respective con-
trol cell lines, the number of migrating cells was higher in the condition of FGFR4-388Arg overexpression in all 
cell lines under study (Fig. 3C and Supplementary Figure S2). These results indicate that FGFR4-388Arg has a role 
in inducing an EMT phenotype in lung cancer.
The pro-oncogenic role of FGFR4-388Arg depends on N-cadherin expression. As N-cadherin 
expression has been linked to oncogenicity25–27, we hypothesized that the overexpression of this adhesion 
molecule may underlie the pro-tumorigenic potential of FGFR4-388Arg expression. To evaluate this hypoth-
esis, we silenced N-cadherin expression in the FGFR4-388Arg-overexpressing H2009 cell line (Fig. 4A) and 
performed surrogate assays to ascertain the role of N-cadherin in the induced pro-oncogenic properties. 
N-cadherin downregulation decreased the clonogenicity and soft agar colony formation compared to the FGFR4-
388Arg-overexpressing cell line and the empty vector control cell line (Fig. 4B,C), and the same effects were 
reported in vivo in tumor growth of xenografts in inmunodeprived mice with these cell lines (Fig. 4D). These 
results support the dependence of FGFR4-388Arg on N-cadherin to promote oncogenic activity.
STAT3 inhibition reduces the FGFR4-388Arg-induced overexpression of N-cadherin in vitro. 
As STAT3 activation has been related to EMT, we examined whether STAT3 over-activation is involved in the 
induction of N-cadherin expression, which our data showed to be relevant in the pro-oncogenic effects of FGFR4-
388Arg overexpression. We abrogated STAT3 activation in the FGFR4-388Arg-overexpressing H2009 and H226 
cell lines with a selective STAT3 inhibitor, SI3-201, and measured N-cadherin protein levels at different time 
points. Inhibition of pSTAT3 levels was confirmed after 4 hours of treatment, and a reduction in N-cadherin 
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Figure 1. Effect of the overexpression of the 388Gly and 388Arg variants of FGFR4 in the tumorigenic abilities 
of the inmortalized NL20, the lung SCC H226 and Calu-1, and the H2009 and HCC827 lung ADC cell lines. 
(A) 10% FBS growth curves. (B) soft agar assays showing the relative colony number quantification (left) and 
representative images (right). (C) Western blot determination of activation of cancer-related signalling pathways 
of 388Gly and 388Arg FGFR4-overexpressing cell lines. In soft agar assay, colony number representation is 
shown. All values were normalized to empty vector control for each replicate of the experiment, and the mean 
and standard deviation of every normalized replicate are represented. For western blotting, cells were serum 
starved for 5 hours and then the protein extraction was made. For the serum stimulated conditions, after 
serum starvation cells were stimulated with serum-containing complete medium for fifteen minutes before 
protein extraction. p-Values are represented as asterisks (*p < 0,05; **p < 0,01; ***p < 0,001). EV = Empty 
Vector control, FGFR4-Gly = FGFR4-388Gly overexpressing, FGFR4-Arg = FGFR4-388Arg overexpressing, 
FBS = Fetal Bovine Serum.
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protein levels was reported after 16–24 hours of treatment, with a dramatic reduction at 48 hours (Fig. 4E). These 
results indicate that STAT3 signaling mediates the induction of N-cadherin expression.
To gain mechanistic insight into these phenomena, we assessed the activation of the STAT3, AKT and MAPK 
signaling pathways under different conditions in the H2009 lung ADC cell line (Fig. 4F). FGFR4-388Arg over-
expression in H2009 cells activated the STAT3, AKT and MAPK signaling pathways compared to control and 
FGFR4-388Gly-overexpressing cells, as shown before. Treatment with SI3-201, the STAT3 inhibitor, abrogated 
STAT3 activation in all cell lines. This inhibition did not influence the activation of AKT or MAPK in control cells 
or FGFR4-388Gly-overexpressing cells. However, STAT3 inhibition reduced AKT and MAPK activation in paral-
lel with N-cadherin expression in FGFR4-388Arg-overexpressing H2009 cells. Furthermore, N-cadherin silenc-
ing in the FGFR4-388Arg-overexpressing cell line dramatically inhibited AKT and MAPK activation (Fig. 4F). 
These results show that FGFR4-388Arg elicits STAT3 activation, which induces N-cadherin expression, and that 
N-cadherin is likely necessary for the consequent activation of AKT and MAPK.
FGFR4-388Arg expression correlates with higher N-cadherin expression in human tumors. 
We determined the FGFR4 Gly388Arg genotype and the mRNA expression of FGFR4 and N-cadherin in a cohort 
of 65 NSCLC tumors using DNA and RNA extracted from FFPE tumor samples. The characteristics of this patient 
cohort are shown in Supplementary Table S2. Patients were divided in two groups according to FGFR4 Gly388Arg 
genotype: homozygous for FGFR4-388Gly (N = 43) and heterozygous for the FGFR4-388Arg variant (N = 22). 
No homozygous FGFR4-388Arg patients were detected in our cohort. No significant differences between clinico-
pathological characteristics were found between both patient subgroups. In agreement with our in vitro results, 
we found an association between the FGFR4-388Arg genotype and higher N-cadherin expression in these sam-
ples (Fig. 5A). Furthermore, when we selected patients with the 388Arg variant, there was a correlation between 
FGFR4 and N-cadherin mRNA expression in the whole cohort (Spearman’s coefficient = 0.751, p = 0.008), the 
ADC group (Spearman’s coefficient = 0.649, p = 0.038) and the SCC group (Spearman’s coefficient = 0.678, 
p = 0.043) (Fig. 5B). Such correlation was not observed in the FGFR4-388 Gly expressing variant subgroup (data 
not shown).
The FGFR4-388Arg variant correlates with poorer survival in NSCLC patients with high FGFR4 
expression. Next, the FGFR4 Gly388Arg genotype was correlated with prognosis in patients with high 
FGFR4 mRNA expression. We selected the 75% of patients with the highest expression in our cohort (Quartile 
2-Quartile 4). We found that the FGFR4-388Arg variant correlated with poorer PFS and OS (p < 0.001 and 
p = 0.002, respectively; Fig. 6A). This prognostic effect for OS was independent of histology (ADC, p = 0.041; 
SCC, p = 0.017; Fig. 6B); the same trend was observed for PFS, but statistical significance was not reached 
(Fig. 6B). However, when we performed multivariate analysis in these patients, we reported that the FGFR4-
388Arg variant was not an independent prognostic factor (data not shown).
Discussion
In this work, we report the pro-oncogenic role of the FGFR4-388Arg variant in lung cancer; this variant correlates 
with greater STAT3 and MAPK activation and higher expression of EMT markers in vitro. This pro-tumorigenic 
role is mediated by the induction of N-cadherin expression, which requires STAT3 overactivation. At the clinical 
level, we report a correlation between the FGFR4-388Arg variant and higher N-cadherin expression in lung tum-
ors, as well as an association of this FGFR4 variant with poorer outcomes for patients with NSCLC, regardless of 
histology.
The FGFR4-388Arg variant correlates with disease progression and poorer prognosis in several types of can-
cer9–15. However, the relationship between this variant and prognosis in NSCLC remains unclear16–18 and the 
effects of this FGFR4 variant in lung pro-tumorigenicity have not been addressed. We report that in the lung cell 
Figure 2. In vivo effects of the overexpression of the 388Gly and 388Arg variants in the H2009 ADC and 
H226 SCC cell lines. Relative tumor growth representation of the xenografts generated in immunodeprived 
nude mice of the reported cell lines. p-values are represented as asterisks (*p < 0,05; **p < 0,01; ***p < 0,001). 
EV = Empty Vector control, FGFR4-Gly = FGFR4-388Gly overexpressing, FGFR4-Arg = FGFR4-388Arg 
overexpressing.
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Figure 3. Overexpression of the 388Arg variant of FGFR4 induces the expression of EMT markers in lung 
cell lines. The mRNA (A) and protein (B) expression of four EMT markers (N-cadherin, vimentin, Twist1 
and Snail1) was performed in the control empty vector (EV), FGFR4-388Gly-overexpressing (FGFR4-Gly) 
and FGFR4-388Arg-overexpressing (FGFR4-Arg) lung immortalized NL20 cell line and lung SCC H226 
and Calu1, and ADC H2009 and HCC827 cell lines. (C) Relative number of migrated cells of the previously 
mentioned cell lines. The mRNA measurements were performed in three independent experiments and mean 
expression values, represented as 2−ΔCt with their respective standard deviation, are represented. For western 
blots, a representative blot is shown. Migration assays were performed in three independent experiments. All 
values were normalized to empty vector control for each replicate of the experiment and the mean and standard 
deviation of every normalized replicate are represented. p-values are represented as asterisks (*p < 0,05; 
**p < 0,01; ***p < 0,001, ns = non significant). EV = Empty Vector control, FGFR4-Gly = FGFR4-388Gly 
overexpressing, FGFR4-Arg = FGFR4-388Arg overexpressing.
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Figure 4. N-cadherin is involved in the pro-oncogenic role of Arg388 FGFR4 overexpression. (A) N-cadherin 
silencing in the FGFR4-388Arg-overexpressing H2009 cell line using a shRNA approach. Clonability (B) and soft 
agar assays (C) of the FGFR4-388Arg-overexpressing, N-cadherin silenced H2009 cell line. (D) Relative tumor 
growth of the xenograft in immunodeprived nude mice of these cell lines. (E) Western blot showing the STAT3 
activation suspension by the STAT3 inhibitor SI3-201 along the time, which is accompanied by N-cadherin protein 
levels reduction, in the FGFR4-388Arg-overexpressing H2009 and H226 cell lines. SI3-201 exposure in hours is 
indicated in the figure. (F) Western blot showing the effect of STAT3 inhibition and N-cadherin shRNA silencing 
in several cancer-related downstream signaling pathways in the EV, FGFR4-388Gly and -388Arg-overexpressing 
H2009 cell line. In soft agar and clonability assays, colony number representation is shown. All values were 
normalized to empty vector control for each replicate of the experiment and the mean and standard deviation 
of every normalized replicate are represented. For western blots, a representative blot is shown. EV = Empty 
Vector control, FGFR4-Gly = FGFR4-388Gly overexpressing, FGFR4-Arg = FGFR4-388Arg overexpressing. 
p-Values are represented as asterisks (*p < 0,05; **p < 0,01; ***p < 0,001). EV1 = Empty Vector 1, EV2 = Empty 
vector 2, FGFR4-Gly = FGFR4-388Gly overexpressing, FGFR4-Arg = FGFR4-388 FGFR4 overexpressing, shN1-
cad = N-cadherin shRNA 1 silenced, shN2-cad = N-cadherin shRNA 2 silenced.
www.nature.com/scientificreports/
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lines tested, overexpression of FGFR4-388Arg elicited greater pro-tumorigenic effects in vitro and in vivo than 
overexpression of the FGFR4-388Gly variant or the empty vector control, independent of histological origin. At 
a molecular level, this increase in tumorigenic behavior induced by FGFR4-388Arg was accompanied by greater 
STAT3 and MAPK activation. The substitution of the conserved glycine 388 residue with an arginine residue in 
FGFR4 exposes a STAT3 binding site, which enhances STAT3 tyrosine phosphorylation21. This may explain the 
overactivation of STAT3 reported in the FGFR4-388Arg-overexpressing cell lines. FGFR4-388Gly overexpres-
sion exerted pro-oncogenic effects in most of the cell lines under study compared to the empty vector control 
cell lines, but unexpectedly caused anti-tumorigenic effects in one of the ADC cell lines. Another member of the 
Figure 5. Arg388 FGFR4 mRNA expression correlates with N-cadherin mRNA expression. (A) N-cadherin 
mRNA expression levels according to Arg388 FGFR4 mRNA expression. (B) Bivariate correlation analysis of 
Arg388 FGFR4 and N-cadherin mRNA expression levels in the whole NSCLC cohort and in the ADC and SCC 
patient subsets. Gly = FGFR4-388Gly, Arg = FGFR4-388Arg.
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FGFR family, FGFR3, has been suggested to exert anti-oncogenic effects in certain contexts in pancreatic cancer 
cell lines28, and FGFR4 could behave similarly under specific molecular backgrounds. However, the potential 
anti-tumorigenic role of FGFR4-388Gly should be reproduced in additional lung cancer cell lines and further 
studied in order to be confirmed.
Figure 6. Correlation of FGFR4 variant and prognosis in high FGFR4 mRNA expressing NSCLC patients. 
(A) Overall and progression-free survival curves for high FGFR4 mRNA expressing patients, according to the 
FGFR4 variant in the whole NSCLC cohort. (B) Overall and progression-free survival analysis of SCC and ADC 
patient subsets depending on the FGFR4 variant, taking into account exclusively the groups with high FGFR4 
mRNA expression. Gly = FGFR4-388Gly, Arg = FGFR4-388Arg.
www.nature.com/scientificreports/
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It has been reported that FGFR4 silencing in FGFR4-388Arg-expressing prostate cancer cell lines leads to the 
induction of E-cadherin expression and to decreased N-cadherin expression29, suggesting that FGFR4-388Arg 
may be related to EMT. To ascertain if FGFR4-388Arg induces an EMT phenotype in lung cell lines upon over-
expression, the expression of several EMT markers (N-cadherin, Twist1, vimentin, and Snail1) was assessed by 
RT-qPCR and western blot. We confirmed that this FGFR4 variant is potentially involved in inducing EMT, 
as every EMT marker tested showed increased expression exclusively in the cell lines overexpressing FGFR4-
388Arg, which furthermore showed increased migration ability. N-cadherin has been extensively implicated in 
cancer progression25,30,31 and in anti-apoptotic mechanisms in NSCLC cell lines26. Thus, we hypothesized that 
N-cadherin could be mediating the pro-oncogenic effects observed in these cell lines, so we downregulated 
N-cadherin expression in the FGFR4-388Arg-overexpressing H2009 lung ADC cell line, and determined the 
effects on tumorigenesis by performing surrogate assays. Our data showed that in this cell line, N-cadherin silenc-
ing reduced MAPK and AKT signaling, and reversed the pro-oncogenic effects of FGFR4-388Arg overexpres-
sion in vitro and in vivo, supporting the hypothesis that N-cadherin upregulation in response to FGFR4-388Arg 
overexpression is involved in the increased pro-oncogenic activity caused by this FGFR4 variant. In accordance 
with our results, pro-tumorigenic effects accompanied by MAPK overactivation have been reported in the con-
text of N-cadherin and FGFR co-expression32, and AKT activation by this adhesion molecule has been reported 
in several contexts33,34, which may explain the increase in oncogenic signaling and pro-tumorigenicity upon 
N-cadherin induction by the FGFR4-388Arg variant.
Next, we wanted to elucidate the mechanism by which FGFR4-388Arg overexpression is pro-tumorigenic. 
Overexpression of this FGFR4 variant caused STAT3 overactivation. Constitutive STAT3 signaling has 
been related to EMT; this signaling pathway has been reported to be involved in downregulating epithelial 
phenotype-related genes and inducing a mesenchymal phenotype35–37. In hepatocellular carcinoma, STAT3 binds 
to the Twist promoter and induces its expression, thus triggering EMT and N-cadherin expression37. Considering 
these data, we aimed to determine if STAT3 overactivation caused by FGFR4-388Arg overexpression is linked 
to N-cadherin upregulation. Therefore, we analyzed the effects of a STAT3 selective inhibitor on N-cadherin 
protein levels in FGFR4-388Arg-overexpressing cell lines. STAT3 inhibition decreased N-cadherin protein 
expression, supporting the idea that constitutive activation of the STAT3 signaling pathway is involved in upreg-
ulating N-cadherin. In the H2009 cell line, the STAT3 inhibitor abrogated STAT3 activation in both FGFR4-
388Gly- and FGFR4-388Arg-overexpressing conditions but, interestingly, decreased AKT and MAPK activation, 
accompanied by N-cadherin downregulation, in only the FGFR4-388Arg-overexpressing cell line. Furthermore, 
N-cadherin silencing in the FGFR4-388Arg-overexpressing cell line decreased the activation of the AKT and 
MAPK signaling pathways. These results suggest that N-cadherin upregulation is linked to MAPK overactivation 
in response to FGFR4-388Arg overexpression, independent of STAT3 activation. All these data support a model 
wherein FGFR4-388Arg increases STAT3 activation, which consequently upregulates N-cadherin expression. 
Then, N-cadherin upregulation increases AKT and MAPK signaling, which may be ultimately responsible for the 
pro-oncogenic characteristics reported in these cell lines.
We provide clinical evidence that FGFR4-388Arg is associated with higher N-cadherin mRNA expression 
in a cohort of NSCLC patients. We found a correlation between N-cadherin and FGFR4 mRNA expression in 
patients with the FGFR4-388Arg variant. These data are in accordance with our in vitro results, which showed 
that FGFR4-388Arg overexpression increased N-cadherin expression levels.
In previous retrospective studies, the association of the FGFR4-388Arg genotype to prognosis in lung cancer 
patients has remained controversial13,16–19. Some of them independently analyzing NSCLC histological subtypes 
agreed on a potential prognostic role of this variant in ADC patients13,19, and in lymph node-affected squamous 
cell carcinoma patients19,20. In our patient cohort that included patients with ADC, SCC and a few other histo-
logic types of lung cancer, we found that the FGFR4-388Arg variant correlated with poor OS and PFS in patients 
with high FGFR4 mRNA expression. Furthermore, when we independently analyzed the SCC or ADC patients, 
FGFR4-388Arg-expressing tumors correlated with worse OS and showed a correlation trend with PFS in both 
patient subsets, suggesting that FGFR4-388Arg expression may have a prognostic role in both histologic types. 
For all the prognosis analyses presented herein, we considered only patients with high FGFR4 mRNA expression; 
we discarded patients with low or absent FGFR4 gene expression. This criterion was formulated because expres-
sion of the variant is required for it to exert any effects. In contrast, previously published studies in the context of 
NSCLC considered only the FGFR4 allelic variant, not gene expression, in the tumor. This may explain why these 
previous results were not reproducible in the different cohorts. However, multivariate analysis of survival in these 
patients did not support the independent prognostic capacity of the FGFR4 variant, which may be explained by 
the relatively low number of patients included in our analysis. Our results should be further confirmed in inde-
pendent cohorts including a higher number of patients, and considering not only the FGFR4 variant present in 
the tumor, but also its expression level.
In summary, we have shown here that the FGFR4-388Arg variant has an impact on the tumorigenic behavior 
of lung cancer cell lines by inducing an EMT expression profile through increased N-cadherin expression and 
overactivation of MAPK and AKT signaling. Furthermore, we report clinical evidence that this variant has a 
potential prognostic role in lung cancer patients with tumors that express high levels of FGFR4. We provide in 
vitro, in vivo, mechanistic and clinical data supporting the potential pro-oncogenic and prognostic role of the 
FGFR4-388Arg variant in NSCLC.
Methods
Cell lines and transfections. The NL20, H226, Calu-1, HCC827 and H2009 cell lines were purchased from 
American Type Culture Collection (ATCC) at the beginning of this study and were cultured according to instruc-
tions from ATCC. Cells were authenticated and regularly checked for mycoplasma contamination.
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Cell lines were transfected with overexpression plasmids (pCMV6, PS100001, Origene) carrying the FGFR4-
388Gly (RG204230, Origene) or the FGFR4-388Arg (RC402575, Origene) alleles using TransIT-X2 transfection 
reagent (Mirus). The empty vector was transfected into the cell lines as a negative control. For N-cadherin silenc-
ing, shRNAs in the pB-RS plasmid were purchased from Origene (HC138304). Two different shRNAs successfully 
downregulating N-cadherin expression were used for further experiments to avoid off-target effects. The appro-
priate antibiotic (1 mg/mL G418 or 1-4 µg/mL blasticidin) was used to select positive clones, which were pooled 
in a monolayer culture to generate stable cell lines.
Immunoblotting. Protein was extracted from cell lines using RIPA buffer (Sigma) supplemented with a 
protease inhibitor cocktail (cOmplete Mini EDTA-free, Roche) and a phosphatase inhibitor cocktail (PhosSTOP 
EASYpack, Roche). A standard western blot protocol was utilized with a miniProtean electrophoretic system 
(BioRad) and a semi-dry electrotransfer system (BioRad). Primary antibodies against FGFR4 (#8562, Cell 
Signaling), AKT (#9272, Cell Signaling), pAKT (#9271, Cell Signaling), ERK1/2 (#9102, Cell Signaling), pERK1/2 
(#9101, Cell Signaling), STAT3 (#9139, Cell Signaling), pSTAT3 (#9145, Cell Signaling), N-cadherin (#3195, Cell 
Signaling), Vimentin (#5741, Cell Signaling), Twist (#46702 S, Cell Signaling), Snail (#3879 S, Cell Signaling) and 
α-tubulin (#T9026, Sigma) were used. α-Tubulin protein expression was used as the loading control. Horseradish 
peroxidase-conjugated secondary antibodies were used for chemiluminescence-based detection of protein 
expression in the ChemiDoc detection system (BioRad). No grouping of gels/blots cropped from different parts 
of the same gel, or from different gels, fields, or exposures was performed.
Cell line stimulation. Cell lines were stimulated with fetal bovine serum (FBS) in culture media at a rou-
tine concentration: 10% FBS for H226 and H2009 cells and 4% for NL20 cells. Cells were incubated in FBS-free 
medium for five hours to achieve the basal phosphorylation state. Then, the cells were stimulated by the addition 
of growth medium for 15 minutes, and protein extracts were obtained as indicated above.
STAT3 inhibition. STAT3 inhibition experiments were performed using the SI3-201 inhibitor (Selleckchem). 
The IC20 (concentration at which growth is reduced at 20% in 48 hours) was calculated38 and applied to the 
cell line under assessment in complete growth medium. Culture medium with the inhibitor was renewed after 
24 hours. Protein was extracted at 4, 8, 16, 24 and 48 hours.
Cell line RNA extraction and analysis. RNA was extracted from cell lines using Trizol Reagent (Life 
Technologies) and then reverse transcribed with the TaqMan Reverse Transcription Kit (Life Technologies). 
Gene expression analysis was performed using TaqMan probes from Life Technologies: Hs00983056_m1 FAM 
(N-cadherin), Hs00195591_m1 (SNAI1), Hs01675818_s1 (TWIST1), Hs00185584_m1 (VIM) and Hs99999905_
m1 FAM (GAPDH). GAPDH was used as a reference gene to normalize expression data.
Clonogenicity assays. A limited number of cells, typically 3000, corresponding to the clonogenic density 
was seeded in 10-cm cell culture plates. Each condition was seeded in triplicate per assay, and each assay was 
repeated a minimum of three times. Medium was renewed once a week during the assay, and after two or three 
weeks, depending on the cell line, the plates were fixed with 0.5% glutaraldehyde for 20-30 minutes. Then, the cells 
were stained with a 1% crystal violet solution in water. The plates were washed and the colonies counted.
Growth curves. A total of 3500 cells per well were seeded in 12-well culture plates (Nunc) in complete 
growth medium. Three replicates per condition were assayed in each growth curve, and a minimum of three rep-
licate growth curves were generated for each experiment. The first point of the curve (day 0) was fixed with a 0.5% 
glutaraldehyde solution 24 hours after seeding. In the 0.5% FBS growth curves, cells were washed twice with PBS, 
and medium containing 0.5% FBS was then added before the day 0 plate was fixed. Every two days, a point on the 
curve was fixed and stored in PBS at 4 °C until the last point of the curve was fixed. Cells were then stained with 
a 1% crystal violet solution and washed. The crystal violet that attached to the cells was dissolved in a 20% acetic 
acid/water solution, and the absorbance of this solution at 595 nm was measured. The intensity of the absorbance 
correlates with the quantity of cells, and the data were normalized to the absorbance on day 0. The normalized 
absorbance over time is presented.
Soft agar assays. A total of 100,000 cells per well in 0.35% agarose growth medium were seeded in 6-well 
plates over a base of 0.7% agarose medium. The day after seeding, 3 mL of complete growth medium was added to 
each well. The media was replaced twice a week until the end of the experiment, at which point the colonies had 
undergone sufficient growth. Then, photos were taken of each well with microscope (#IX2-SLP, Olympus) with an 
installed camera (#U-CMAD3, Olympus), and colony number and size were determined.
Migration assays. Cells were tripsinized, counted, and included in FBS-free medium. 150.000 cells in 1.5 mL 
of FBS-free medium were added to 8 µM pore size 6-well transwells (#3428. Cultek). Transwells were placed on 
6-well plates including 2.5 mL of 10% FBS medium. After 48 hours of incubation, transwell were discarded and 
migrated cells attached to the well bottom were fixed and stained with a 1% crystal violet solution. The crystal vio-
let that attached to the cells was dissolved in a 20% acetic acid/water solution, and the absorbance of this solution 
at 595 nm was measured. The intensity of the absorbance correlates with the quantity of migrated cells.
Mouse xenograft and tumor growth assessment. Cell lines were trypsinized, counted and diluted in 
PBS. Then, the cell suspension was mixed with Matrigel (1:1), and 150 µL (containing 1 × 106 cells) of the mixture 
was injected into both flanks of female, 6-week-old athymic nude mice (nu+/nu+). 5 animals were included in 
each group to reach statistical significance, based on previous experiments in the laboratory, and reviewed and 
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approved by the Animal Protection Comittee. Tumors were measured weekly after implantation, and the mice 
were sacrificed when the tumor volume exceeded 1000 mm3. Then, tumors were harvested and stored.
Clinical specimens. The present study involved 65 subjects from the Virgen del Rocio University Hospital 
(Seville, Spain). Patients had undergone surgical resection, and tumor samples were sent to the pathology labora-
tory for diagnosis and were prepared for storage by formalin fixation and paraffin embedding.
Ethical issues. Regarding human samples, written informed consent was provided by all the patients. The 
project was approved by the Research Ethics Committee of the Virgen del Rocío University Hospital, Sevilla, 
Spain (Approval ID: 2012PI/241).
The procedures involving animals were approved by Animal Protection of the Comunidad Autónoma de 
Madrid (Approval ID: PROEX134/16).
All experiments were performed in accordance with relevant guidelines and regulations. Biobanking and 
handling of the human samples followed the BRISQ guidelines39. And, for tumor marker prognostic study, the 
REMARK reporting guidelines were followed40.
Genotyping. DNA was extracted from tissue sections of formalin-fixed, paraffin-embedded (FFPE) sam-
ples using the QIAamp DNA Mini Kit (#51306, QIAGEN), and the DNA concentration was measured using 
a Nanodrop ND-1000 spectrophotometer (Nanodrop Tech). DNA samples were then preamplified using 
Preamplification Master Mix (#4384266, Applied Biosystems) and the rs351855 TaqMan Genotyping probe 
(#4351379, Applied Biosystems), following the manufacturer’s instructions, with an 18-cycle preamplification 
protocol; then, the samples were diluted 1:20. Genotyping was conducted using the 50-cycle genotyping protocol 
from TaqMan and the rs351855 probe, and the results were analyzed with TaqMan Genotyper software.
RNA extraction from clinical specimens. RNA was extracted from paraffin-embedded tissue from 
patients using the RecoverAll Extraction Kit (#AM1975, Life Technologies). RNA samples were then reverse 
transcribed with the TaqMan Reverse Transcription Kit (Life Technologies). Prior to the analysis of each gene, a 
preamplification step was performed with the TaqMan Preamp Master Mix Kit (#4384266, Applied Biosystems). 
Preamplification and gene expression analysis were conducted using TaqMan probes from Life Technologies: 
Hs01106908_m1 FAM (FGFR4), Hs00983056_m1 FAM (N-cadherin), and Hs99999905_m1 FAM (GAPDH). 
GAPDH was used as the reference gene to normalize the expression data.
Statistical analysis. Statistical analysis was performed with the SPSS statistical package (v19, IBM). 
Differences between experimental conditions were analyzed using Student’s t-test. Spearman’s Rho method was 
used for bivariate correlation analysis. Kaplan-Meier curves were generated to calculate overall survival (OS) and 
progression-free survival (PFS), and significant differences were assessed by log rank univariate and proportional 
hazards regression multivariate analysis. The Chi-Square test was used to assess differences in clinicopathological 
characteristics between the different patient subgroups.
References
 1. Lu, M. et al. TFIIB-related factor 2 over expression is a prognosis marker for early-stage non-small cell lung cancer correlated with 
tumor angiogenesis. PLoS One 9, e88032, https://doi.org/10.1371/journal.pone.0088032 (2014).
 2. Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. The New England journal of medicine 359, 1367–1380, https://doi.
org/10.1056/NEJMra0802714 (2008).
 3. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA: a cancer journal for clinicians 66, 7–30, https://doi.org/10.3322/
caac.21332 (2016).
 4. Quintanal-Villalonga, A., Paz-Ares, L., Ferrer, I. & Molina-Pinelo, S. Tyrosine Kinase Receptor Landscape in Lung Cancer: 
Therapeutical Implications. Disease markers 2016, 9214056, https://doi.org/10.1155/2016/9214056 (2016).
 5. Huang, H. P., Feng, H., Qiao, H. B., Ren, Z. X. & Zhu, G. D. The prognostic significance of fibroblast growth factor receptor 4 in non-
small-cell lung cancer. OncoTargets and therapy 8, 1157–1164, https://doi.org/10.2147/OTT.S81659 (2015).
 6. Roidl, A. et al. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 15, 
2058–2066, https://doi.org/10.1158/1078-0432.CCR-08-0890 (2009).
 7. Hu, L. & Cong, L. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating 
fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer. Oncol Rep 34, 2683–2691, https://doi.org/10.3892/
or.2015.4212 (2015).
 8. Yang, Y. et al. Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma. Mol 
Carcinog 51, 515–521, https://doi.org/10.1002/mc.20805 (2012).
 9. Bange, J. et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62, 840–847 
(2002).
 10. Stadler, C. R., Knyazev, P., Bange, J. & Ullrich, A. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by 
EDG-2 gene repression. Cell Signal 18, 783–794, https://doi.org/10.1016/j.cellsig.2005.07.002 (2006).
 11. da Costa Andrade, V. C. et al. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and 
neck squamous cell carcinoma. Experimental and molecular pathology 82, 53–57, https://doi.org/10.1016/j.yexmp.2006.05.003 
(2007).
 12. Morimoto, Y. et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis 
in high-grade soft tissue sarcoma. Cancer 98, 2245–2250, https://doi.org/10.1002/cncr.11778 (2003).
 13. Spinola, M. et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 23, 
7307–7311, https://doi.org/10.1200/JCO.2005.17.350 (2005).
 14. Streit, S., Mestel, D. S., Schmidt, M., Ullrich, A. & Berking, C. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 
protein expression with survival of melanoma patients. Br J Cancer 94, 1879–1886, https://doi.org/10.1038/sj.bjc.6603181 (2006).
 15. Yang, Y. C. et al. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J 
Cancer 95, 1455–1458, https://doi.org/10.1038/sj.bjc.6603456 (2006).
 16. Sasaki, H. et al. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer. Oncology reports 20, 
1125–1130 (2008).
www.nature.com/scientificreports/
1 2SCIENtIFIC RepoRts |  (2018) 8:2394  | DOI:10.1038/s41598-018-20570-3
 17. Fang, H. M., Tian, G., Zhou, L. J., Zhou, H. Y. & Fang, Y. Z. FGFR4 genetic polymorphisms determine the chemotherapy response 
of Chinese patients with non-small cell lung cancer. Acta pharmacologica Sinica 34, 549–554, https://doi.org/10.1038/aps.2012.206 
(2013).
 18. Matakidou, A. et al. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer 
prognosis. British journal of cancer 96, 1904–1907, https://doi.org/10.1038/sj.bjc.6603816 (2007).
 19. Falvella, F. S. et al. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the 
transcriptional profile of normal lung. International journal of cancer 124, 2880–2885, https://doi.org/10.1002/ijc.24302 (2009).
 20. Quintanal-Villalonga, A. et al. Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With 
Lymph Node Involvement. Clinical lung cancer. https://doi.org/10.1016/j.cllc.2017.05.008 (2017).
 21. Ulaganathan, V. K., Sperl, B., Rapp, U. R. & Ullrich, A. Germline variant FGFR4p.G388R exposes a membrane-proximal STAT3 
binding site. Nature 528, 570–574, https://doi.org/10.1038/nature16449 (2015).
 22. Yu, W. et al. FGFR-4 Arg(3)(8)(8) enhances prostate cancer progression via extracellular signal-related kinase and serum response 
factor signaling. Clinical cancer research: an official journal of the American Association for Cancer Research 17, 4355–4366, https://
doi.org/10.1158/1078-0432.CCR-10-2858 (2011).
 23. Sugiyama, N. et al. FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-
FGFR4 complex. Proc Natl Acad Sci USA 107, 15786–15791, https://doi.org/10.1073/pnas.0914459107 (2010).
 24. Cho, S. H. et al. FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal 
Transition. Cancer research and treatment: official journal of Korean Cancer Association 49, 766–777, https://doi.org/10.4143/
crt.2016.457 (2017).
 25. Araki, K. et al. E/N-cadherin switch mediates cancer progression via TGF-beta-induced epithelial-to-mesenchymal transition in 
extrahepatic cholangiocarcinoma. British journal of cancer 105, 1885–1893, https://doi.org/10.1038/bjc.2011.452 (2011).
 26. Hui, L. et al. Prognostic significance of twist and N-cadherin expression in NSCLC. PloS one 8, e62171, https://doi.org/10.1371/
journal.pone.0062171 (2013).
 27. Hulit, J. et al. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase 
activation. Cancer research 67, 3106–3116, https://doi.org/10.1158/0008-5472.CAN-06-3401 (2007).
 28. Lafitte, M. et al. FGFR3 has tumor suppressor properties in cells with epithelial phenotype. Molecular cancer 12, 83, https://doi.
org/10.1186/1476-4598-12-83 (2013).
 29. Sugiyama, N. et al. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to 
extracellular matrix degradation. Cancer research 70, 7851–7861, https://doi.org/10.1158/0008-5472.CAN-10-1223 (2010).
 30. Heerboth, S. et al. EMT and tumor metastasis. Clinical and translational medicine 4, 6, https://doi.org/10.1186/s40169-015-0048-3 
(2015).
 31. Nitta, T. et al. Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: 
comprehensive immunohistochemical study using a tissue microarray. British journal of cancer 111, 1363–1372, https://doi.
org/10.1038/bjc.2014.415 (2014).
 32. Qian, X. et al. N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like 
properties. Oncogene 33, 3411–3421, https://doi.org/10.1038/onc.2013.310 (2014).
 33. Zhang, J. et al. AKT activation by N-cadherin regulates beta-catenin signaling and neuronal differentiation during cortical 
development. Neural development 8, 7, https://doi.org/10.1186/1749-8104-8-7 (2013).
 34. Tran, N. L., Adams, D. G., Vaillancourt, R. R. & Heimark, R. L. Signal transduction from N-cadherin increases Bcl-2. Regulation of 
the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization. The Journal of biological 
chemistry 277, 32905–32914, https://doi.org/10.1074/jbc.M200300200 (2002).
 35. Liu, R. Y. et al. JAK/STAT3 signaling is required for TGF-beta-induced epithelial-mesenchymal transition in lung cancer cells. 
International journal of oncology 44, 1643–1651, https://doi.org/10.3892/ijo.2014.2310 (2014).
 36. Xiong, H. et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-
mesenchymal transition. The Journal of biological chemistry 287, 5819–5832, https://doi.org/10.1074/jbc.M111.295964 (2012).
 37. Zhang, C., Guo, F., Xu, G., Ma, J. & Shao, F. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human 
hepatocellular carcinoma cells. Oncology reports 33, 1872–1882, https://doi.org/10.3892/or.2015.3783 (2015).
 38. Moneo, V. et al. Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis. BMC cancer 14, 281, https://doi.
org/10.1186/1471-2407-14-281 (2014).
 39. Moore, H. M. et al. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol 119, 92–101, https://doi.
org/10.1002/cncy.20147 (2011).
 40. Altman, D. G., McShane, L. M., Sauerbrei, W. & Taube, S. E. Reporting recommendations for tumor marker prognostic studies 
(REMARK): explanation and elaboration. PLoS Med 9, e1001216, https://doi.org/10.1371/journal.pmed.1001216 (2012).
Acknowledgements
The authors thank the donors and the HUVR-IBiS Biobank (Andalusian Public Health System Biobank and 
ISCIII-Red de Biobancos PT13/0010/0056) for the human specimens used in this study. L.P.A. was funded by 
ISCIII (PI14/01964 and PIE15/00076), CIBER (CB16/12/00442) and RTICC (R12/0036/0028) and co-funded 
by European Union (ERDF/ESF, “Investing in your future”). The laboratory of A.C. was supported by grants 
from the Spanish Ministry of Economy and Competitiveness, PN I+D+I 2008-2011, PE I+D+I 2013-2016, 
ISCIII (PI15/00045 and CB16/12/00275), Consejeria de Ciencia e Innovacion (CTS-1848) and Consejeria de 
Salud of the Junta de Andalucia (PI-0096-2014). S.M.P. is funded by Consejería de Salud y Bienestar Social (PI-
0046-2012), ISCIII (PI17/00033) and co-funded by European Union (ERDF/ESF, “Investing in your future”), 
and Fundación Mutua Madrileña (2014). I.F. is funded by AECC (AIO2015) and Consejería de Igualdad, Salud 
y Políticas Sociales de la Junta de Andalucía (PI-0029-2013) and FIS (PI16/01311). A.Q. is funded by ISCIII 
(FI12/00429). L.O. is funded by Ministerio de Educación, Cultura y Deporte (FPU13/02595).
Author Contributions
Conceptualization, A.Q., I.F., S.M.P., A.C., and L.P.A.; Methodology, A.Q., A.C., I.F., and S.M.P.; Investigation, 
A.Q., A.C., I.F., L.P.A. and S.M.P.; Generation of Figures, A.Q., A.S., A.M., L.O. and P.Y.; Formal Analysis, A.Q., 
I.F. and S.P.A., Writing – Original Draft, A.Q., I.F., A.C., S.M.P. and L.P.A., Writing – Review & Editing, A.Q., I.F., 
A.C., S.M.P. and L.P.A., Supervision, A.C., I.F., S.M.P., and L.P.A.; Funding Acquisition, S.M.P. and L.P.A.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-20570-3.
Competing Interests: The authors declare that they have no competing interests.
www.nature.com/scientificreports/
13SCIENtIFIC RepoRts |  (2018) 8:2394  | DOI:10.1038/s41598-018-20570-3
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
